Table 2. INSTI-resistance mutations identified by population or deep sequencing in 12 HIV-infected individuals participating in the GS-US-183-0105 study of elvitegravir.

Patient	Population Sequencing a	Deep Sequencing (frequency [%]) a
08–175	T66T/A/I/V, S147S/G	T66A (71.1%), L74M (3%), E92Q (6.7%), S147G (74.6%)
08–172	E92E/Q	T66A (4.4%), E92Q (55.1.%)
08–198	T66T/A, E92E/Q, S147S/G	H51Y (11.6%), T66A (2.5%), E92Q (4.1%), S147G (90.5%)
08–183	E92Q	E92Q (99.8%)
08–180	E92Q	E92Q (96.7%)
08–177	N155N/H	N155H (79.9%)
08–194	N155H	T97A (2.9%), N155H (99.8%)
08–201	N155H	N155H (98%)
08–202	E92E/Q, N155N/H	T66I (3.8%), E92Q (30.3%), N155H (59.9%)
08–230	E92Q, N155H	E92Q (99.6%), N155H (98.5%)
08–189	S147S/G, Q148R	T66I (2.7%), E92Q (4%), S147G (33.2%), Q148R (73.5%), S153Y (4%)
08–182	S147G, Q148R	S147G (97.2%), Q148R (99.2%)

^aMajor mutations associated with resistance to INSTI as described [71], [86]. INSTI-resistance mutations identified using deep sequencing but not by population sequencing are indicated in bold.